• Product name
    Anti-MYO6 antibody [MUD-19]
    See all MYO6 primary antibodies
  • Description
    Mouse monoclonal [MUD-19] to MYO6
  • Host species
  • Tested applications
    Suitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide, corresponding to amino acids 291-302 of Human MYO6.

  • Positive control
    • A431 whole cell lysate.


  • Form
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    pH: 7.40
    Preservative: 0.097% Sodium azide
    Constituents: 0.0268% PBS, 1% BSA
  • Concentration information loading...
  • Purity
    Protein A purified
  • Clonality
  • Clone number
  • Isotype
  • Research areas


Our Abpromise guarantee covers the use of ab11095 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
WB Use a concentration of 2 µg/ml. Detects a band of approximately 150 kDa.


  • Function
    Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Myosin 6 is a reverse-direction motor protein that moves towards the minus-end of actin filaments. Has slow rate of actin-activated ADP release due to weak ATP binding. Functions in a variety of intracellular processes such as vesicular membrane trafficking and cell migration. Required for the structural integrity of the Golgi apparatus via the p53-dependent pro-survival pathway. Appears to be involved in a very early step of clathrin-mediated endocytosis in polarized epithelial cells. May act as a regulator of F-actin dynamics. May play a role in transporting DAB2 from the plasma membrane to specific cellular targets. Required for structural integrity of inner ear hair cells.
  • Tissue specificity
    Expressed in most tissues examined including heart, brain, placenta, pancreas, spleen, thymus, prostate, testis, ovary, small intestine and colon. Highest levels in brain, pancreas, testis and small intestine. Also expressed in fetal brain and cochlea. Isoform 1 and isoform 2, containing the small insert, and isoform 4, containing neither insert, are expressed in unpolarized epithelial cells.
  • Involvement in disease
    Defects in MYO6 are the cause of deafness autosomal dominant type 22 (DFNA22) [MIM:606346]. DFNA22 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA22 is progressive and postlingual, with onset during childhood. By the age of approximately 50 years, affected individuals invariably have profound sensorineural deafness.
    Defects in MYO6 are the cause of deafness autosomal recessive type 37 (DFNB37) [MIM:607821].
    Defects in MYO6 are the cause of deafness sensorineural with hypertrophic cardiomyopathy (DFNHCM) [MIM:606346].
  • Sequence similarities
    Contains 1 IQ domain.
    Contains 1 myosin head-like domain.
  • Domain
    Divided into three regions: a N-terminal motor (head) domain, followed by a neck domain consisting of a calmodulin-binding linker domain and a single IQ motif, and a C-terminal tail region with a coiled-coil and a unique globular domain required for interaction with other proteins.
  • Post-translational
    Phosphorylation in the motor domain, induced by EGF, results in translocation of MYO6 from the cell surface to membrane ruffles and affects F-actin dynamics. Phosphorylated in vitro by p21-activated kinase (PAK).
  • Cellular localization
    Cytoplasmic vesicle > clathrin-coated vesicle membrane; Cytoplasmic vesicle > clathrin-coated vesicle membrane. Cell projection > ruffle membrane and Golgi apparatus > trans-Golgi network membrane. Golgi apparatus. Nucleus. Cytoplasm > perinuclear region. Membrane > clathrin-coated pit. Cell projection > ruffle membrane. Also present in endocyctic vesicles, and membrane ruffles. Translocates from membrane ruffles, endocytic vesicles and cytoplasm to Golgi apparatus, perinuclear membrane and nucleus through induction by p53 and p53-induced DNA damage. Recruited into membrane ruffles from cell surface by EGF-stimulation. Colocalizes with DAB2 in clathrin-coated pits/vesicles. Colocalizes with OPTN at the Golgi complex and in vesicular structures close to the plasma membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Deafness autosomal recessive 37 antibody
    • DFNA 22 antibody
    • DFNA22 antibody
    • DFNB 37 antibody
    • DFNB37 antibody
    • KIAA0389 antibody
    • MYO 6 antibody
    • Myo6 antibody
    • MYO6_HUMAN antibody
    • Myosin VI antibody
    • Myosin-VI antibody
    • Myosin6 antibody
    • Unconventional myosin-6 antibody
    • Unconventional myosin-VI antibody
    see all


  • All lanes : Anti-MYO6 antibody [MUD-19] (ab11095) at 1/250 dilution

    All lanes : Whole cell lysate prepared from human breast cell lines

    All lanes : Rabbit anti-mouse conjugated to HRP

    Developed using the ECL technique.

    Exposure time: 10 seconds


ab11095 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Abcam guarantees this product to work in the species/application used in this Abreview.
Western blot
Human Cell lysate - whole cell (Human breast cell lines)
Loading amount
10 µg
Human breast cell lines
Gel Running Conditions
Reduced Denaturing
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C

Dr. Damian Yap

Verified customer

Submitted Apr 21 2011


Sign up